The nasopharyngeal cancer therapeutics markets will reach to $55m by 2019

Tuesday 13 March 2012, Amsterdam

Clinicians treating patients with nasopharyngeal cancer may have to wait for the scientifical breakthrough they seek, as university-funded research on unique treatments may fail to offer a fast alternative, a new report by pharmaceutical market experts.

The new report shows that while the significant risks associated with current treatment options have led medical professionals to demand a new blockbuster drug, research currently being undertaken at various academic institutions around the world lacks the financial backing needed to make a considerable impact on the treatment market.

Current products for nasopharyngeal cancer put patients at risk of several adverse side effects, including neutropenia, thrombocytopenia, anemia, leucopenia and infections resulting from the loss of white blood cells. The global nasopharyngeal cancer therapeutics market therefore offers considerable opportunity for new products to capture market value if they can offer superior efficacy and safety profiles, alongside fewer adverse effects.

A slow increase in the prevalence of nasopharyngeal cancer has led to the expansion of the drug-treated population. The discovery of a curative therapy is likely to attract considerable financial rewards should pharmaceutical companies choose to explore the future market potential.

However, while the current therapeutics pipeline contains eight molecules in various stages of development, all of which are first-in-class (FIC) molecules with novel mechanisms of action, there are no molecules in the late stage of clinical development, and only three molecules are being studied within company-sponsored trials, with five others being investigated by academic institutions and universities. This makes it unlikely that these drugs will make a commercial impact on the future nasopharyngeal cancer therapeutics market.

New molecular targeted agents hold the potential to capture a significant market share, creating scope for novel drugs to enter the market. However, GlobalData’s analysis indicates that future research must show a developed understanding of the molecular and cellular processes underlying tumor biology and metastatic spread to displace the currently available treatments.

They valued the nasopharyngeal cancer therapeutics markets of the US, the UK, Germany, Italy, France, Spain and Japan market at a cumulative $53m in 2011, growing at a Compound Annual Growth Rate (CAGR) of 1.3% throughout 2006-2011. This value is forecast to increase only marginally due to the continued unmet needs of patients, growing at a CAGR of 0.5% to reach $55m by 2019.


Nasopharyngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019

The report is an essential source of information and analysis on the global nasopharyngeal cancer therapeutics market. The report identifies the key trends shaping and driving the global nasopharyngeal cancer therapeutics market. It also provides insights into the current competitive landscape and the emerging players expected to significantly alter the market positions of the current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global nasopharyngeal cancer therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis conducted by GlobalData’s team of industry experts.